The Colocalization Potential of HIV-specific CD8+ and CD4+ T-cells is Mediated by Integrin β7 but Not CCR6 and Regulated by Retinoic Acid
Overview
Authors
Affiliations
CD4(+) T-cells from gut-associated lymphoid tissues (GALT) are major targets for HIV-1 infection. Recruitment of excess effector CD8(+) T-cells in the proximity of target cells is critical for the control of viral replication. Here, we investigated the colocalization potential of HIV-specific CD8(+) and CD4(+) T-cells into the GALT and explored the role of retinoic acid (RA) in regulating this process in a cohort of HIV-infected subjects with slow disease progression. The expression of the gut-homing molecules integrin β7, CCR6, and CXCR3 was identified as a "signature" for HIV-specific but not CMV-specific CD4(+) T-cells thus providing a new explanation for their enhanced permissiveness to infection in vivo. HIV-specific CD8(+) T-cells also expressed high levels of integrin β7 and CXCR3; however CCR6 was detected at superior levels on HIV-specific CD4(+) versus CD8(+) T-cells. All trans RA (ATRA) upregulated the expression of integrin β7 but not CCR6 on HIV-specific T-cells. Together, these results suggest that HIV-specific CD8(+) T-cells may colocalize in excess with CD4(+) T-cells into the GALT via integrin β7 and CXCR3, but not via CCR6. Considering our previous findings that CCR6(+)CD4(+) T-cells are major cellular targets for HIV-DNA integration in vivo, a limited ability of CD8(+) T-cells to migrate in the vicinity of CCR6(+)CD4(+) T-cells may facilitate HIV replication and dissemination at mucosal sites.
IL-32 Drives the Differentiation of Cardiotropic CD4+ T Cells Carrying HIV DNA in People With HIV.
Ramani H, Gosselin A, Bunet R, Jenabian M, Sylla M, Pagliuzza A J Infect Dis. 2023; 229(5):1277-1289.
PMID: 38113908 PMC: 11095560. DOI: 10.1093/infdis/jiad576.
FoxP3 CD8 T-cells in acute HIV infection and following early antiretroviral therapy initiation.
Yero A, Shi T, Routy J, Tremblay C, Durand M, Costiniuk C Front Immunol. 2022; 13:962912.
PMID: 35967314 PMC: 9372390. DOI: 10.3389/fimmu.2022.962912.
Yero A, Farnos O, Clain J, Zghidi-Abouzid O, Rabezanahary H, Racine G J Virol. 2022; 96(7):e0025522.
PMID: 35311550 PMC: 9006892. DOI: 10.1128/jvi.00255-22.
Wacleche V, Cattin A, Goulet J, Gauchat D, Gosselin A, Cleret-Buhot A Blood Adv. 2018; 2(21):2862-2878.
PMID: 30381402 PMC: 6234376. DOI: 10.1182/bloodadvances.2018020123.
Strickland N, Muller T, Berkowitz N, Goliath R, Carrington M, Wilkinson R J Immunol. 2017; .
PMID: 28794233 PMC: 5624500. DOI: 10.4049/jimmunol.1700849.